Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder

Treatments: Drug: Comparator: placebo (unspecified); Drug: aprepitant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00035048

MK0869-068

0869-068

2006_406

Formally-3N25

Details and patient eligibility

About

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Full description

The duration of treatment is 10 weeks.

Enrollment: 540 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients with Major Depressive Disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind